Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database
Laurent Mortier, Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), H. Miotti(IQVIA (France)), Célèste Lebbé(Inserm), E. Maubec(Délégation Paris 7), B van Hille(Merck Serono S.A.S. (France)), F. Aubin, Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), I. Kachaner(Pfizer (France)), Caroline Robert(Inserm), C. Lenormand(Hôpitaux Universitaires de Strasbourg), G. Quéreux(Nantes Université), Mahtab Samimi(Centre Hospitalier Universitaire de Tours), C. Cahuzac(Merck Serono S.A.S. (France)), Laura Luciani(Merck Serono S.A.S. (France)), Astrid Blom(Université de Versailles Saint-Quentin-en-Yvelines), Pascal Joly(Hôpital Charles-Nicolle), M.N. Solbes(Merck Serono S.A.S. (France))
Cited by 8
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k